배란 유도제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 6.6%의 연평균 복합 성장률(CAGR)로 61억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 라이프스타일의 변화와 출산 지연, 디지털 건강의 통합, 시장 범위의 확대, 불임률 증가, 맞춤형 치료 요법 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 개인 맞춤형 치료 접근법, 생식 내분비학의 발전, 비침습적 가임력 모니터링, 보조생식술에 대한 수요 증가, 새로운 약물 제제 개발 등이 있습니다.
여성 불임의 유병률 증가는 배란 유도제 시장의 성장을 가속할 것으로 예상됩니다. 여성 불임은 피임 없이 장기간(보통 1년 이상) 정기적으로 성관계를 가졌음에도 불구하고 임신이 되지 않거나, 임신이 되더라도 임신에 이르지 못하는 생물학적 상태로 정의됩니다. 배란 유도제는 불규칙한 배란 또는 배란 부족과 관련된 문제를 해결하여 여성의 불임을 치료하는 데 사용됩니다. 이 약물은 배란 과정에 관여하는 호르몬 경로를 표적으로 삼아 난소를 자극하여 성숙한 난자를 방출하도록 자극합니다. 예를 들어, 미국 정부 기관인 질병통제예방센터(CDC)에 따르면 2022년에는 미국 15-44세 여성 중 약 610만 명이 임신에 어려움을 겪을 것으로 예상되며, 이는 전체 여성의 약 10%에 해당합니다. 또한 미국의 의료 관리 회사 CCRM Management Company LLC가 2022년 6월에 보고한 바와 같이, 불임은 전 세계 평균적으로 4쌍 중 1쌍의 부부에게 영향을 미치며, 매년 5%에서 10%씩 증가하고 있습니다. 이처럼 여성 불임의 유병률 증가는 배란 유도제 시장의 성장을 가속하고 있습니다.
체외수정(IVF)을 선택하는 환자 증가는 향후 몇 년 동안 배란 유도제 시장의 성장을 가속할 것으로 예상됩니다. 체외수정은 불임 문제가 있는 개인이나 부부의 임신을 돕기 위해 고안된 복잡한 일련의 절차입니다. IVF 프로토콜은 배란 유도제를 사용하여 난소를 자극하고 난자를 채취하기 위해 여러 개의 난자를 생산하도록 유도합니다. 이러한 약물은 체외수정(IVF) 과정에 필수적이며 성공 가능성을 높입니다. 예를 들어, 2024년 4월, 미국에 본사를 둔 의사와 실험 과학자를 대표하는 조직인 보조생식술학회는 난자 동결 주기가 크게 증가하여 전년도 24,560건에서 2022년 29,803건으로 증가했다고 보고했습니다. 이에 따라 체외수정을 선택하는 환자 증가가 배란 유도제 시장 확대에 박차를 가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 배란 유도제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
- 최종 이용 산업 분석
- 세계의 배란 유도제 시장 : 성장률 분석
- 세계의 배란 유도제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 배란 유도제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 배란 유도제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 배란 유도제 시장 약제 클래스별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 호르몬
- 치료제
- 세계의 배란 유도제 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 비경구
- 기타 투여 경로
- 세계의 배란 유도제 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 홈케어
- 전문 클리닉
- 기타 최종사용자
- 세계의 배란 유도제 시장 : 호르몬별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- Gonadotropins
- Clomiphene Citrate
- Aromatase Inhibitors
- 세계의 배란 유도제 시장 치료제 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- Metformin
- Letrozole
- Bromocriptine
제7장 지역별/국가별 분석
- 세계의 배란 유도제 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 배란 유도제 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 배란 유도제 시장 : 경쟁 구도
- 배란 유도제 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Johnson And Johnson Pvt Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
- Bayer AG
- Sanofi SA
- Abbott Laboratories
- Gilead Sciences Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Janssen Pharmaceutical Inc.
- Mylan N.V
- Astellas Pharma Inc.
- Sun Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Dr Reddy's Laboratories Ltd.
- Intas Pharmaceuticals Limited
- Endo International Inc.
- Ferring Pharmaceuticals Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 배란 유도제 시장(2029년) : 새로운 기회를 제공하는 국가
- 배란 유도제 시장(2029년) : 새로운 기회를 제공하는 부문
- 배란 유도제 시장(2029년) : 성장 전략
제36장 부록
LSH
Ovulation-inducing drugs are medications used to stimulate the ovaries and facilitate the release of mature eggs (ovulation) in women facing challenges with their menstrual cycles or struggling with infertility. These drugs exert their effects on the hormonal balance in the body, specifically targeting the hormones involved in the ovulation process.
The primary types of ovulation-inducing drugs include hormones and therapeutic drugs. Hormone drugs are medications designed to modify or mimic the effects of naturally occurring hormones in the body. They can be administered through oral, topical, and other routes and are utilized by various end-users, including hospitals, homecare, specialty clinics, and others.
The ovulation-inducing drug market research report is one of a series of new reports from The Business Research Company that provides ovulation-inducing drug market statistics, including ovulation-inducing drug industry global market size, regional shares, competitors with a ovulation-inducing drug market share, detailed ovulation-inducing drug market segments, market trends and opportunities, and any further data you may need to thrive in the ovulation-inducing drug industry. This ovulation-inducing drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to development of clomiphene citrate, introduction of letrozole, regulatory approvals and standardization, emergence of ovulation predictor kits.
The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $6.12 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to changing lifestyles and delayed childbearing, digital health integration, expanding market reach, rising infertility rates, customized treatment regimens. Major trends in the forecast period include personalized treatment approaches, advancements in reproductive endocrinology, non-invasive fertility monitoring, rising demand for assisted reproductive technologies, development of novel drug formulations.
The rising prevalence of infertility among women is expected to drive the growth of the ovulation-inducing drug market. Women's infertility is defined as the biological condition where a woman is unable to conceive or carry a pregnancy to term after engaging in regular, unprotected sexual intercourse for an extended period, typically a year or more. Ovulation-inducing drugs are utilized to treat infertility in women by addressing issues related to irregular or absent ovulation. These medications target the hormonal pathways involved in the ovulation process, stimulating the ovaries to release mature eggs. For instance, according to the Centers for Disease Control and Prevention, a US government agency, in 2022, approximately 6.1 million women aged 15 to 44 in the US faced challenges in becoming pregnant, representing about 10% of all women. Additionally, as reported in June 2022 by CCRM Management Company LLC, a US-based medical management firm, infertility impacts 1 in 4 couples globally on average, with an annual increase of 5% to 10%. Thus, the growing prevalence of women's infertility is propelling the growth of the ovulation-inducing drug market.
The increasing number of patients choosing in vitro fertilization (IVF) is anticipated to drive the growth of the ovulation-inducing drugs market in the coming years. IVF is a complex set of procedures designed to assist individuals and couples experiencing fertility issues in achieving pregnancy. The IVF protocols utilize ovulation-inducing drugs to stimulate the ovaries, leading to the production of multiple eggs for retrieval. These medications are integral to the IVF process, enhancing the likelihood of successful outcomes. For example, in April 2024, The Society for Assisted Reproductive Technology, a US-based organization representing doctors and laboratory scientists, reported a significant rise in egg-freezing cycles, which increased from 24,560 the previous year to 29,803 in 2022. Consequently, the growing number of patients opting for IVF is fueling the expansion of the ovulation-inducing drugs market.
Major companies in the ovulation-inducing drugs market are proactively developing innovative drugs such as Cetrorelix acetate to secure approvals for treating women undergoing controlled ovarian stimulation. Cetrorelix acetate for injection, a gonadotropin-releasing hormone (GnRH) antagonist, has gained FDA approval, demonstrating its efficacy in preventing premature ovulation in women undergoing in vitro fertilization (IVF). In August 2022, Akorn Operating Company LLC received FDA approval for a generic version of cetrorelix acetate for injection, marking a significant advancement in fertility treatment. This development is aligned with the ongoing efforts of pharmaceutical companies, such as Akorn, to address infertility through innovative drugs.
In February 2024, Novo Holdings, a Denmark-based life sciences company, acquired Catalent Inc. for $16.5 billion. This acquisition is intended to bolster Novo Holdings' presence in the life sciences sector by utilizing Catalent's advanced capabilities in drug development, manufacturing, and delivery. The aim is to enhance innovation, streamline drug development processes, and broaden its global healthcare reach, particularly in high-demand areas such as biologics, gene therapies, and specialized drug delivery technologies. Catalent Inc., based in the US, provides a range of pharmaceuticals, including ovulation-inducing drugs.
Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.
North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the ovulation inducing drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The ovulation-inducing drugs market consists of sales of clomiphene citrate (Clomid), letrozole (Femara), gonadotropins, human chorionic gonadotropin (hCG), bromocriptine (Cycloset, Parlodel). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ovulation Inducing Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ovulation inducing drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ovulation inducing drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ovulation inducing drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: Hormones; Therapeutics Drugs
- 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
- 3) By End-User: Hospital; Homecare; Specialty Clinics; Other End-Users
- Subsegments:
- 1) By Hormones: Gonadotropins; Clomiphene Citrate; Aromatase Inhibitors
- 2) By Therapeutic Drugs: Metformin; Letrozole; Bromocriptine
- Companies Mentioned: Pfizer Inc.; Johnson And Johnson Pvt Ltd.; Merck And Co. Inc.; Abbvie Inc.; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Ovulation Inducing Drugs Market Characteristics
3. Ovulation Inducing Drugs Market Trends And Strategies
4. Ovulation Inducing Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Ovulation Inducing Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Ovulation Inducing Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Ovulation Inducing Drugs Market Growth Rate Analysis
- 5.4. Global Ovulation Inducing Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Ovulation Inducing Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Ovulation Inducing Drugs Total Addressable Market (TAM)
6. Ovulation Inducing Drugs Market Segmentation
- 6.1. Global Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hormones
- Therapeutics Drugs
- 6.2. Global Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Routes Of Administration
- 6.3. Global Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End-Users
- 6.4. Global Ovulation Inducing Drugs Market, Sub-Segmentation Of Hormones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gonadotropins
- Clomiphene Citrate
- Aromatase Inhibitors
- 6.5. Global Ovulation Inducing Drugs Market, Sub-Segmentation Of Therapeutic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Metformin
- Letrozole
- Bromocriptine
7. Ovulation Inducing Drugs Market Regional And Country Analysis
- 7.1. Global Ovulation Inducing Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Ovulation Inducing Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Ovulation Inducing Drugs Market
- 8.1. Asia-Pacific Ovulation Inducing Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Ovulation Inducing Drugs Market
- 9.1. China Ovulation Inducing Drugs Market Overview
- 9.2. China Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Ovulation Inducing Drugs Market
- 10.1. India Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Ovulation Inducing Drugs Market
- 11.1. Japan Ovulation Inducing Drugs Market Overview
- 11.2. Japan Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Ovulation Inducing Drugs Market
- 12.1. Australia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Ovulation Inducing Drugs Market
- 13.1. Indonesia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Ovulation Inducing Drugs Market
- 14.1. South Korea Ovulation Inducing Drugs Market Overview
- 14.2. South Korea Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Ovulation Inducing Drugs Market
- 15.1. Western Europe Ovulation Inducing Drugs Market Overview
- 15.2. Western Europe Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Ovulation Inducing Drugs Market
- 16.1. UK Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Ovulation Inducing Drugs Market
- 17.1. Germany Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Ovulation Inducing Drugs Market
- 18.1. France Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Ovulation Inducing Drugs Market
- 19.1. Italy Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Ovulation Inducing Drugs Market
- 20.1. Spain Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Ovulation Inducing Drugs Market
- 21.1. Eastern Europe Ovulation Inducing Drugs Market Overview
- 21.2. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Ovulation Inducing Drugs Market
- 22.1. Russia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Ovulation Inducing Drugs Market
- 23.1. North America Ovulation Inducing Drugs Market Overview
- 23.2. North America Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Ovulation Inducing Drugs Market
- 24.1. USA Ovulation Inducing Drugs Market Overview
- 24.2. USA Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Ovulation Inducing Drugs Market
- 25.1. Canada Ovulation Inducing Drugs Market Overview
- 25.2. Canada Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Ovulation Inducing Drugs Market
- 26.1. South America Ovulation Inducing Drugs Market Overview
- 26.2. South America Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Ovulation Inducing Drugs Market
- 27.1. Brazil Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Ovulation Inducing Drugs Market
- 28.1. Middle East Ovulation Inducing Drugs Market Overview
- 28.2. Middle East Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Ovulation Inducing Drugs Market
- 29.1. Africa Ovulation Inducing Drugs Market Overview
- 29.2. Africa Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Ovulation Inducing Drugs Market Competitive Landscape And Company Profiles
- 30.1. Ovulation Inducing Drugs Market Competitive Landscape
- 30.2. Ovulation Inducing Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson And Johnson Pvt Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Ovulation Inducing Drugs Market Other Major And Innovative Companies
- 31.1. Bayer AG
- 31.2. Sanofi SA
- 31.3. Abbott Laboratories
- 31.4. Gilead Sciences Inc.
- 31.5. Amgen Inc.
- 31.6. Teva Pharmaceutical Industries Ltd.
- 31.7. Janssen Pharmaceutical Inc.
- 31.8. Mylan N.V
- 31.9. Astellas Pharma Inc.
- 31.10. Sun Pharmaceuticals Industries Ltd.
- 31.11. Aurobindo Pharma Limited
- 31.12. Dr Reddy's Laboratories Ltd.
- 31.13. Intas Pharmaceuticals Limited
- 31.14. Endo International Inc.
- 31.15. Ferring Pharmaceuticals Inc.
32. Global Ovulation Inducing Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Ovulation Inducing Drugs Market
34. Recent Developments In The Ovulation Inducing Drugs Market
35. Ovulation Inducing Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Ovulation Inducing Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Ovulation Inducing Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Ovulation Inducing Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
